Gilead Takes Calistoga To Boost Cancer Effort
This article was originally published in Start Up
Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.
You may also be interested in...
For an myelodysplastic syndrome and pancreatic cancer drug, the diversified pharma and device company paid $50 million upfront, plus a generous $515 million in milestones that could pay out before the drug is even commercialized.
“Emerging growth” start-ups will enjoy less regulation during their first five years as public companies, easing the burden on new listings while giving IPO prospects more leverage against buyers.
A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.